These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31424709)

  • 1. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis.
    Bhatia N; Stein Gold L; Kircik LH; Schreiber R
    J Drugs Dermatol; 2019 Aug; 18(8):790-796. PubMed ID: 31424709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
    Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S
    J Drugs Dermatol; 2017 Mar; 16(3):234-240. PubMed ID: 28301619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
    Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
    J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
    Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
    J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
    Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
    Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis.
    Katz HI; Gross E; Buxman M; Prawer SE; Schwartzel EH; Gibson JR
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1175-8. PubMed ID: 1757613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies.
    Bernhard J; Whitmore C; Guzzo C; Kantor I; Kalb RE; Ellis C; Urbach F; Schwartzel EH; Gibson JR
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1170-4. PubMed ID: 1757612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
    Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
    J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
    [No Abstract]   [Full Text] [Related]  

  • 10. Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants.
    Cook-Bolden FE; Hebert AA; Guenthner ST; Kang R; Martin G; Jacobson A
    J Drugs Dermatol; 2020 Aug; 19(8):747-754. PubMed ID: 32845589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
    Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
    J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
    Green LJ; Kerdel FA; Cook-Bolden FE; Bagel J; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Drugs Dermatol; 2018 Oct; 17(10):1062-1069. PubMed ID: 30365586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
    Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions.
    Gottlieb AB; Ford RO; Spellman MC
    J Cutan Med Surg; 2003; 7(3):185-92. PubMed ID: 12704534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
    Tyring S; Kircik LH; Yamauchi P; Jacobson A; Lin T
    J Drugs Dermatol; 2020 Apr; 19(4):389-396. PubMed ID: 32272516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants.
    Desai SR; Glick B; Del Rosso JQ; Harris S; Jacobson A
    J Drugs Dermatol; 2021 Mar; 20(3):252-258. PubMed ID: 33683083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
    Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
    J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.
    Lebwohl M; Sherer D; Washenik K; Krueger GG; Menter A; Koo J; Feldman SR
    Int J Dermatol; 2002 May; 41(5):269-74. PubMed ID: 12100701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
    Stein Gold L; Elewski B; Draelos Z; Jacobson A; Lin T
    J Drugs Dermatol; 2020 May; 19(5):504-514. PubMed ID: 32484629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.